Editorial: Immunology of allogeneic hematopoietic stem cell transplantation.
作者信息
Gurnari Carmelo, Dulery Remy, Greco Raffaella, Piccinelli Sara
机构信息
Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy.
Translational Hematology and Oncology Research Department, Taussig Cancer Center, Cleveland Clinic, Cleveland, OH, United States.
出版信息
Front Transplant. 2025 Feb 19;4:1567882. doi: 10.3389/frtra.2025.1567882. eCollection 2025.
Abstract
摘要
相似文献
1
Editorial: Immunology of allogeneic hematopoietic stem cell transplantation.社论：异基因造血干细胞移植的免疫学
Front Transplant. 2025 Feb 19;4:1567882. doi: 10.3389/frtra.2025.1567882. eCollection 2025.
2
Case Report: Unedited allogeneic chimeric antigen receptor T cell bridging to conditioning-free hematopoietic stem cell transplantation for a child with refractory Burkitt lymphoma.病例报告：未编辑的同种异体嵌合抗原受体 T 细胞桥接无预处理造血干细胞移植治疗难治性伯基特淋巴瘤患儿。
Front Immunol. 2023 Sep 6;14:1219872. doi: 10.3389/fimmu.2023.1219872. eCollection 2023.
3
Hematopoietic stem cell graft manipulation as a mechanism of immunotherapy.造血干细胞移植操作作为一种免疫治疗机制。
Int Immunopharmacol. 2003 Aug;3(8):1121-43. doi: 10.1016/S1567-5769(03)00014-6.
4
Integrating CAR T-Cell Therapy and Transplantation: Comparisons of Safety and Long-Term Efficacy of Allogeneic Hematopoietic Stem Cell Transplantation After CAR T-Cell or Chemotherapy-Based Complete Remission in B-Cell Acute Lymphoblastic Leukemia.嵌合抗原受体 T 细胞疗法与移植的整合：CAR T 细胞或基于化疗的完全缓解后异基因造血干细胞移植在 B 细胞急性淋巴细胞白血病中的安全性和长期疗效比较。
Front Immunol. 2021 May 7;12:605766. doi: 10.3389/fimmu.2021.605766. eCollection 2021.
5
Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.异基因反应性作为血液系统恶性肿瘤治疗的治疗原则。非清髓性预处理的异基因造血细胞移植的临床和免疫学方面的研究。
Dan Med Bull. 2007 May;54(2):112-39.
6
Allogeneic T Cells That Express an Anti-CD19 Chimeric Antigen Receptor Induce Remissions of B-Cell Malignancies That Progress After Allogeneic Hematopoietic Stem-Cell Transplantation Without Causing Graft-Versus-Host Disease.表达抗CD19嵌合抗原受体的同种异体T细胞可诱导异基因造血干细胞移植后进展的B细胞恶性肿瘤缓解，且不引起移植物抗宿主病。
J Clin Oncol. 2016 Apr 1;34(10):1112-21. doi: 10.1200/JCO.2015.64.5929. Epub 2016 Jan 25.
7
Impact of SARS-CoV-2 in Hematopoietic Stem Cell Transplantation and Chimeric Antigen Receptor T Cell Therapy Recipients.新型冠状病毒对造血干细胞移植和嵌合抗原受体 T 细胞治疗受者的影响。
Transplant Cell Ther. 2021 Sep;27(9):796.e1-796.e7. doi: 10.1016/j.jtct.2021.07.005. Epub 2021 Jul 10.
8
[Advances in Allogeneic Chimeric Antigen Receptor T Cells].[异基因嵌合抗原受体T细胞的进展]
Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2023 Dec 30;45(6):967-972. doi: 10.3881/j.issn.1000-503X.15325.
9
Potential alternatives to αβ-T cells to prevent graft-versus-host disease (GvHD) in allogeneic chimeric antigen receptor (CAR)-based cancer immunotherapy: A comprehensive review.预防同种异体嵌合抗原受体 (CAR) 为基础的癌症免疫疗法中移植物抗宿主病 (GvHD) 的 αβ-T 细胞潜在替代物：全面综述。
Pathol Res Pract. 2024 Oct;262:155518. doi: 10.1016/j.prp.2024.155518. Epub 2024 Aug 10.
10
Donor CD7 Chimeric Antigen Receptor T Cell Bridging to Allogeneic Hematopoietic Stem Cell Transplantation for T Cell Hematologic Malignancy.供者 CD7 嵌合抗原受体 T 细胞桥接异基因造血干细胞移植治疗 T 细胞血液恶性肿瘤。
Transplant Cell Ther. 2023 Mar;29(3):167-173. doi: 10.1016/j.jtct.2022.11.013. Epub 2022 Nov 24.
本文引用的文献
1
Celebrating the registration of 9.000 patients treated with CAR T cells in the EBMT registry: Collection of real-world data in the context of hematopoietic cellular therapies.庆祝在 EBMT 注册中心有 9000 名接受 CAR T 细胞治疗的患者注册：在造血细胞治疗背景下收集真实世界数据。
Best Pract Res Clin Haematol. 2024 Jun;37(2):101557. doi: 10.1016/j.beha.2024.101557. Epub 2024 Jun 28.
2
Hematopoietic cell transplantation and cellular therapies in Europe 2022. CAR-T activity continues to grow; transplant activity has slowed: a report from the EBMT.欧洲 2022 年造血细胞移植和细胞治疗。嵌合抗原受体 T 细胞（CAR-T）治疗持续增长；移植治疗活动放缓：来自 EBMT 的报告。
Bone Marrow Transplant. 2024 Jun;59(6):803-812. doi: 10.1038/s41409-024-02248-9. Epub 2024 Mar 4.
3
Pooled allogeneic faecal microbiota MaaT013 for steroid-resistant gastrointestinal acute graft-versus-host disease: a single-arm, multicentre phase 2 trial.用于类固醇难治性胃肠道急性移植物抗宿主病的同种异体粪便微生物群MaaT013：一项单臂、多中心2期试验。
EClinicalMedicine. 2023 Jul 26;62:102111. doi: 10.1016/j.eclinm.2023.102111. eCollection 2023 Aug.
4
Leukemia relapse via genetic immune escape after allogeneic hematopoietic cell transplantation.异基因造血细胞移植后通过遗传免疫逃逸导致白血病复发。
Nat Commun. 2023 May 31;14(1):3153. doi: 10.1038/s41467-023-38113-4.
5
Individual HLA heterogeneity and its implications for cellular immune evasion in cancer and beyond.个体 HLA 异质性及其对癌症及其他疾病中细胞免疫逃逸的影响。
Front Immunol. 2022 Sep 5;13:944872. doi: 10.3389/fimmu.2022.944872. eCollection 2022.
6
The similarity of class II HLA genotypes defines patterns of autoreactivity in idiopathic bone marrow failure disorders.Ⅱ类 HLA 基因型的相似性定义了特发性骨髓衰竭疾病中自身反应的模式。
Blood. 2021 Dec 30;138(26):2781-2798. doi: 10.1182/blood.2021012900.
7
The MAGIC algorithm probability is a validated response biomarker of treatment of acute graft-versus-host disease.MAGIC 算法概率是一种经过验证的急性移植物抗宿主病治疗反应生物标志物。
Blood Adv. 2019 Dec 10;3(23):4034-4042. doi: 10.1182/bloodadvances.2019000791.
Zotero 插件